Medicinal Products

722. Deputy Sorca Clarke asked the Minister for Health the reason that a person (details supplied), who is a medical card holder and is pre diabetic, has been refused a drug prescribed by their GP; the financial supports that are available to this person in accessing this drug; and if she will make a statement on the matter. [50926/26]

727. Deputy Niamh Smyth asked the Minister for Health if she will urgently review the case of a person (details supplied); if she will provide an update on the pain management supports available to them in the interim period prior to their scheduled nerve block procedure; and if she will make a statement on the matter. [50954/26]

730. Deputy Sean Fleming asked the Minister for Health the reasoning behind the proposed changes to providing supplements that people require for their health without having to take prescribed drugs (details supplied); and if she will make a statement on the matter. [50958/26]

745. Deputy Danny Healy-Rae asked the Minister for Health for an update on a matter regarding prescription medication for a person (details supplied); and if she will make a statement on the matter. [51005/26]

746. Deputy Claire Kerrane asked the Minister for Health whether she intends to make a device (details supplied) reimbursable for people with diabetes type 2, as those with type 1 have access to reimbursement; and if she will make a statement on the matter. [51013/26]

755. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to provide the data on the number of pharmacy reimbursement claims adjusted and the number successfully appealed in each year from 2020 to date (details supplied).; and if she will make a statement on the matter. [51052/26]

756. Deputy Ken O'Flynn asked the Minister for Health whether the Primary Care Reimbursement Service holds a national dataset recording the number of pharmacy reimbursement claims adjusted and the number successfully appealed; and if no such dataset is held, to state this plainly; and if she will make a statement on the matter. [51053/26]

757. Deputy Ken O'Flynn asked the Minister for Health to set out the formal mechanism, if any, by which a pharmacy may appeal a rejected reimbursement claim; the average time to determination; the number and proportion of such appeals upheld in each year from 2020 to date; and if she will make a statement on the matter. [51054/26]

758. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to reconcile the figures provided in the reply, given that the difference between claims submitted (details supplied); and if she will make a statement on the matter. [51055/26]

759. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, recording "eligibility expired" as the leading reason for pharmacy claim rejection in the years 2020 to 2022, peaking at 30,005 rejections in 2021; the assessment that has been made of the impact on patients dispensed medicines whose eligibility had lapsed at point of dispensing, includ…

764. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to now provide those figures for each year, or to confirm that no such data is held by the Health Service Executive (details supplied). [51061/26]

765. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, to clarify whether the figure provided for the number of pharmacy reimbursement claims rejected in each year counts unique claims finally refused or counts error events including claims that were subsequently paid; and the reason the combined total of claims approved and claims rejected…

766. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, in which "claim set to pay or already paid" appears among the top five recorded reasons for claim rejection; to provide and the number of pharmacy reimbursement claims that were initially rejected and subsequently paid in each year from 2020 to date, or to confirm that this is not separ…

767. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, whether a formal appeals mechanism exists for rejected pharmacy reimbursement claims; if so, the body responsible for deciding such appeals; and the number of appeals received and the number upheld in each year from 2020 to date. [51064/26]

771. Deputy Cian O'Callaghan asked the Minister for Health to provide an update on the work her Department is doing to progress the pricing and reimbursement application (details supplied) for welireg (belzutifan); and if she will make a statement on the matter. [51110/26]

773. Deputy Denise Mitchell asked the Minister for Health the steps she is taking to ensure that the drug belzutifan is available and accessible to those who need it; and if she will make a statement on the matter. [51144/26]

795. Deputy Albert Dolan asked the Minister for Health if she has engaged with the Minister for Finance regarding the application of VAT to certain vaccines and prescribed medical products; if changes are under consideration; and if she will make a statement on the matter. [51289/26]

818. Deputy Barry Heneghan asked the Minister for Health the current status of the health technology assessment and reimbursement process for the medicine belzutifan for the treatment of eligible patients with Von Hippel-Lindau (VHL) syndrome; the expected timelines for completion of the assessment and any subsequent reimbursement decision; and if she will make a statement on the matter. [51420/26…

819. Deputy Barry Heneghan asked the Minister for Health the steps her Department and the HSE are taking to facilitate timely access to belzutifan for eligible patients with Von Hippel-Lindau (VHL) syndrome, if approved for reimbursement; whether engagement has taken place, or is planned, with clinicians, patient representative organisations and other relevant stakeholders regarding access to this…

820. Deputy Johnny Mythen asked the Minister for Health if belzutifan will be made be available to people suffering from Von Hippel- Lindau disease; and if she will make a statement on the matter. [51422/26]

833. Deputy Naoise Ó Muirí asked the Minister for Health the status of negotiations regarding belzutifan; whether she will expedite the assessment and approval process; and if she will make a statement on the matter. [51584/26]

834. Deputy Naoise Ó Muirí asked the Minister for Health the review she intends to take of Ireland's system for approving access and funding for new drugs and medical treatments; and if she will make a statement on the matter. [51585/26]

840. Deputy Eamon Scanlon asked the Minister for Health the steps being taken to expedite the assessment and approval of belzutifan for patients with Von Hippel–Lindau (VHL) disease to ensure timely access for eligible patients; if she will engage with clinicians and patient groups regarding barriers to access; and if she will make a statement on the matter. [51615/26]

857. Deputy Ryan O'Meara asked the Minister for Health if a pricing and reimbursement application has been received by the HSE for zolbetuximab (vyloy); and if she will make a statement on the matter. [51755/26]

858. Deputy Ryan O'Meara asked the Minister for Health for an update on the pricing and reimbursement application for omaveloxolone (skyclarys); if the commercial proposal has yet been received from the company; and if she will make a statement on the matter. [51756/26]